Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
American Journal of Clinical Dermatology
Erschienen in: American Journal of Clinical Dermatology 6/2005

01.12.2005 | Current Opinion

Oral Contraceptives and Skin Cancer

Is There a Link?

verfasst von: Professor Kimberly K. Leslie, Eve Espey

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 6/2005

Einloggen, um Zugang zu erhalten

Abstract

The skin expresses estrogen, progesterone, and androgen receptors. In the presence of steroid hormones, such as those contained in oral contraceptives, the skin likely responds to hormonal signals that control the cell cycle, apoptosis, DNA replication, and other cellular functions. Some estrogen-responsive pathways have the potential to promote tumor development, including the augmentation of epidermal growth factor signaling, the expression of proto-oncogenes, and inhibition of apoptosis. The question of whether oral contraceptives increase the risk for the development of skin cancer, particularly melanoma, is still an area of concern. This paper reviews the available evidence, the bulk of which suggests that while the skin responds to estrogens, progestins, and androgens, these responses do not significantly increase the risk of developing skin cancer when estrogen exposure is not excessive.
Literatur
1.
2.
Evans RM. The steroid and thyroid hormone receptor superfamily. Science. 1988; 240 (4854): 889–95PubMedCrossRef
3.
Onate SA, Tsai SY, Tsai MJ, et al. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science. 1995; 270 (5240): 1354–7PubMedCrossRef
4.
Carroll JS, Swarbrick A, Musgrove EA, et al. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. Cancer Res 2002; 62 (11): 3126–31PubMed
5.
Webb P, Nguyen P, Valentine C, et al. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol. 1999; 13 (10): 1672–85PubMedCrossRef
6.
Kushner PJ, Agard DA, Greene GL, et al. Estrogen receptor pathways to AP-1. J Steroid Biochem Mot Biol. 2000; 74 (5): 311–7CrossRef
7.
Kushner PJ, Agard D, Feng WJ, et al. Oestrogen receptor function at classical and alternative response elements. Novartis Found Symp. 2000; 230: 20–6PubMedCrossRef
8.
Horwitz KB, Alexander PS. In situ photolinked nuclear progesterone receptors of human breast cancer cells: subunit molecular weights after transformation and translocation. Endocrinology. 1983; 113 (6: 2195–201PubMedCrossRef
9.
Lessey BA, Alexander PS, Horwitz KB. The subunit structure of human breast cancer progesterone receptors: characterization by chromatography and photoaffinity labeling. Endocrinology. 1983; 112 (4): 1267–74PubMedCrossRef
10.
Arnett-Mansfield RL, deFazio A, Wain GV, et al. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res. 2001; 61 (11): 4576–82PubMed
11.
Hanekamp EE, Kuhne EC, Smid-Koopman E, et al. Loss of progesterone receptor may lead to an invasive phenotype in human endometrial cancer. Fur J Cancer. 2002; 38 Suppl. 6: S71–2
12.
Gregory CW, He B, Wilson EM. The putative androgen receptor-A form results from in vitro proteolysis. J Mol Endocrinol. 2001; 27 (3): 309–19PubMedCrossRef
13.
Tilley WD, Marcelli M, Wilson JD, et al. Characterization and expression of a cDNA encoding the human androgen receptor. Proc Natl Acad Sci U S A. 1989; 86 (1): 327–31PubMedCrossRef
14.
Wilson CM, McPhaul MI. A and B forms of the androgen receptor are present in human genital skin fibroblasts. Proc Natl Acad Sci U S A. 1994; 91 (4): 1234–8PubMedCrossRef
15.
Catalano MG, Pfeffer U, Raineri M, et al. Altered expression of androgen-receptor isoforms in human colon-cancer tissues. Int J Cancer. 2000; 86 (3): 325–30PubMedCrossRef
16.
Ho KJ, Liao JK. Nonnuclear actions of estrogen. Arterioscler Thromb Vase Biol. 2002; 22 (12): 1952–61CrossRef
17.
McCann JP, Mayes JS, Hendricks GR, et al. Subcellular distribution and glycosylation pattern of androgen receptor from sheep omental adipose tissue. J Endocrinol; 2001; 169 (3): 587–93PubMedCrossRef
18.
Harvey BJ, Doolan CM, Condliffe SB, et al. Non-genomic convergent and divergent signaling of rapid responses to aldosterone and estradiol in mammalian colon. Steroids. 2002; 67 (6): 483–91PubMedCrossRef
19.
Singleton DW, Feng Y, Burd CJ, et al. Nongenomic activity and subsequent c-fos induction by estrogen receptor ligands are not sufficient to promote deoxyribonucleic acid synthesis in human endometrial adenocarcinoma cells. Endocrinology. 2003; 144 (1): 121–8PubMedCrossRef
20.
Filardo EJ. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol. 2002; 80 (2): 231–8PubMedCrossRef
21.
Filardo EJ, Quinn JA, Frackelton AR, et al. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and CAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol. 2002; 16 (1): 70–84PubMedCrossRef
22.
Ahola TM, Alkio N, Manninen T, et al. Progestin and G protein-coupled receptor 30 inhibit mitogen-activated protein kinase activity in MCF-7 breast cancer cells. Endocrinology. 2002; 143 (12): 4620–6PubMedCrossRef
23.
Ahola TM, Manninen T, Alkio N, et al. G protein-coupled receptor 30 is critical for a progestin-induced growth inhibition in MCF-7 breast cancer cells. Endocrinology. 2002; 143 (9): 3376–84PubMedCrossRef
24.
Ahola TM, Purmonen S, Pennanen P, et al. Progestin upregulates G-protein-coupled receptor 30 in breast cancer cells. Eur J Biochem. 2002; 269 (10): 2485–90PubMedCrossRef
25.
Fraser D, Padwick ML, Whitehead M, et al. Presence of an oestradiol receptor-related protein in the skin: changes during the normal menstrual cycle. Br J Obstet Gynaecol. 1991; 98 (12): 1277–82PubMedCrossRef
26.
Pelletier G, El-Alfy M. Immunocytochemical localization of estrogen receptors alpha and beta in the human reproductive organs. J Clin Endocrinol Metab. 2000; 85 (12): 4835–40PubMedCrossRef
27.
Sun J, Baudry J, Katzenellenbogen JA, et al. Molecular basis for the subtype discrimination of the estrogen receptor-beta-selective ligand, diarylpropionitrile. Mol Endocrinol. 2003; 17 (2): 247–58PubMedCrossRef
28.
Sun J, Huang YR, Harrington WR, et al. Antagonists selective for estrogen receptor alpha. Endocrinology. 2002; 143 (3): 941–7PubMedCrossRef
29.
Shiau AK, Barstad D, Radek IT, et al. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol. 2002; 9 (5): 359–64PubMed
30.
Harris HA, Katzenellenbogen JA, Katzenellenbogen BS. Characterization of the biological roles of the estrogen receptors, ERα and ERβ, in estrogen target tissues in vivo through the use of an ERa-selective ligand. Endocrinology. 2002; 143 (11): 4172–7PubMedCrossRef
31.
Rickard DJ, Waters KM, Ruesink TJ, et al. Estrogen receptor isoform-specific induction of progesterone receptors in human osteoblasts. J Bone Miner Res. 2002; 17 (4): 580–92PubMedCrossRef
32.
Lindberg MK, Moverare S, Skrtic S, et al. Estrogen receptor (ER)-β reduces ERα-regulated gene transcription, supporting a ‘ying yang’ relationship between ERα and ERβ in mice. Mol Endocrinol. 2003; 17 (2): 203–8PubMedCrossRef
33.
Moverare S, Lindberg MK, Faergemann J, et al. Estrogen receptor-α, but not estrogen receptor-β, is involved in the regulation of the hair follicle cycling as well as the thickness of epidermis in male mice. J Invest Dermatol. 2002; 119 (5): 1053–8PubMedCrossRef
34.
Avila DM, Wilson CM, Nandi N, et al. Immunoreactive AR and genetic alterations in subjects with androgen resistance and undetectable AR levels in genital skin fibroblast ligand-binding assays. J Clin Endocrinol Metab. 2002; 87 (1): 182–8PubMedCrossRef
35.
Alesci S, Bornstein SR. Neuroimmunoregulation of androgens in the adrenal gland and the skin. Horm Res. 2000; 54 (5-6): 281–6PubMedCrossRef
36.
Labrie F, Luu-The V, Labrie C, et al. Intracrinology and the skin. Horm Res. 2000; 54 (5-6): 218–29PubMedCrossRef
37.
Nelson LR, Bulun SE. Estrogen production and action. J Am Acad Dermatol. 2001; 45 (3 Suppl.): S116–24PubMedCrossRef
38.
Izu K, Yamamoto O, Yamaguchi J, et al. A case of autoimmune progesterone dermatitis [in German]. J Uoeh. 2001; 23 (4): 431–6PubMed
39.
Uotinen N, Puustinen R, Pasanen S, et al. Distribution of progesterone receptor in female mouse tissues. Gen Comp Endocrinol. 1999; 115 (3): 429–41PubMedCrossRef
40.
Kommoss F, Kiechle-Schwarz M, Dubois A, et al. Co-cultivation of ovarian carcinoma cells with dermal fibroblasts induces fibroblast expression of sex steroid receptor transcripts and protein. Int J Gynecol Cancer. 1995; 5 (2): 101–6PubMedCrossRef
41.
Im S, Lee ES, Kim W, et al. Expression of progesterone receptor in human keratinocytes. J Korean Med Sci. 2000; 15 (6: 647–54PubMed
42.
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002; 288 (3): 321–33PubMedCrossRef
43.
Brekelmans CT. Risk factors and risk reduction of breast and ovarian cancer. Curr Opin Obstet Gynecol. 2003; 15 (1): 63–8PubMedCrossRef
44.
Matsumum Y, Ananthaswamy HN. Molecular mechanisms of photocarcinogenesis. Front Biosci. 2002; 7: d765–83CrossRef
45.
Nataraj AJ, Trent JC, Ananthaswamy HN. p53 gene mutations and photocarcinogenesis. Photochem Photobiol. 1995; 62 (2): 218–30PubMedCrossRef
46.
Nishigori C, Yarosh DB, Donawho C, et al. The immune system in ultraviolet carcinogenesis. J Investig Dermatol Symp Proc. 1996; 1 (2): 143–6PubMed
47.
van Steeg H, Kraemer KH. Xeroderma pigmentosum and the role of UV-induced DNA damage in skin cancer. Mol Med Today. 1999; 5 (2): 86–94PubMedCrossRef
48.
McGregor JM, Yu CC, Dublin EA, et al. Aberrant expression of p53 tumour-suppressor protein in non-melanoma skin cancer. Br J Dermatol. 1992; 127 (5): 463–9PubMedCrossRef
49.
Shea CR, McNutt NS, Volkenandt M, et al. Overexpression of p53 protein in basal cell carcinomas of human skin. Am J Pathol. 1992; 141 (1): 25–9PubMed
50.
Stephenson TJ, Royds J, Silcocks PB, et al. Mutant p53 oncogene expression in keratoacanthoma and squamous cell carcinoma. Br J Dermatol. 1992; 127 (6): 566–70PubMedCrossRef
51.
Kimonis VE, Goldstein AM, Pastakia B, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet. 1997; 69 (3): 299–308PubMedCrossRef
52.
Pierceall WE, Goldberg LH, Tainsky MA, et al. Ras gene mutation and amplification in human nonmelanoma skin cancers. Mol Carcinog. 1991; 4 (3): 196–202PubMedCrossRef
53.
Pierceall WE, Mukhopadhyay T, Goldberg LH, et al. Mutations in the p53 tumor suppressor gene in human cutaneous squamous cell carcinomas. Mol Carcinog. 1991; 4 (6): 445–9PubMedCrossRef
54.
Dai D, Litman ES, Schonteich E, et al. Progesterone regulation of activating protein-1 transcriptional activity: a possible mechanism of progesterone inhibition of endometrial cancer cell growth. J Steroid Biochem Mol Biol. 2003; 87 (2-3): 123–31PubMedCrossRef
55.
Dai D, Wolf DM, Litman ES, et al. Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res. 2002; 62 (3): 881–6PubMed
56.
Rogers GS, Flowers JL, Pollack SV, et al. Determination of sex steroid receptor in human basal cell carcinoma. J Am Acad Dermatol. 1988; 18 (5 Pt 1): 1039–43PubMedCrossRef
57.
Gefeller O, Hassan K, Wille L. Cutaneous malignant melanoma in women and the role of oral contraceptives. Br J Dermatol. 1998; 138 (1): 122–4PubMedCrossRef
58.
Miller JG, Gee J, Price A, et al. Investigation of oestrogen receptors, sex steroids and soluble adhesion molecules in the progression of malignant melanoma. Melanoma Res. 1997; 7 (3): 197–208PubMedCrossRef
59.
Ladanyi A, Timar J, Bocsi J, et al. Sex-dependent liver metastasis of human melanoma lines in SCID mice. Melanoma Res. 1995; 5 (2): 83–6PubMedCrossRef
60.
Kanda N, Watanabe S. 17beta-estradiol, progesterone, and dihydrotestosterone suppress the growth of human melanoma by inhibiting interleukin-8 production. J Invest Dermatol. 2001; 117 (2): 274–83PubMedCrossRef
61.
Richardson B, Price A, Wagner M, et al. Investigation of female survival benefit in metastatic melanoma. Br J Cancer. 1999; 80 (12): 2025–33PubMedCrossRef
62.
Beral V, Ramcharan S, Faris R. Malignant melanoma and oral contraceptive use among women in California. Br J Cancer. 1977; 36 (6): 804–9PubMedCrossRef
63.
Pfahlberg A, Hassan K, Wille L, et al. Systematic review of case-control studies: oral contraceptives show no effect on melanoma risk. Public Health Rev. 1997; 25 (3-4): 309–15PubMed
64.
Karagas MR, Stukel TA, Dykes J, et al. A pooled analysis of 10 case-control studies of melanoma and oral contraceptive use. Br J Cancer. 2002; 86 (7): 1085–92PubMedCrossRef
65.
Feskanich D, Hunter DJ, Willett WC, et al. Oral contraceptive use and risk of melanoma in premenopausal women. Br J Cancer. 1999; 81 (5): 918–23PubMedCrossRef
Metadaten
Titel
Oral Contraceptives and Skin Cancer
Is There a Link?
verfasst von
Professor Kimberly K. Leslie
Eve Espey
Publikationsdatum
01.12.2005
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 6/2005
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200506060-00002

Weitere Artikel der Ausgabe 6/2005

American Journal of Clinical Dermatology 6/2005 Zur Ausgabe

BookReview

Book Reviews

Review Article

The Role of Hyaluronic Acid in Wound Healing

Leading Article

Monitoring Liver Function during Methotrexate Therapy for Psoriasis

Review Article

The Psychosocial Burden of Psoriasis

Review Article

Human Papillomavirus

Original Research Article

Comparison of Azelaic Acid and Anthralin for the Therapy of Patchy Alopecia Areata

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise